Lab Groups’ LDT Comments Will Highlight Barriers To Test Accessibility

Laboratory groups, who are facing the prospect of a new regulatory scheme in FDA’s proposed lab-developed test framework, intend to discuss barriers to test accessibility and clinical validation of LDTs in future comments.